Proteome Regulatory News (PRM)

28 Oct 2009 07:00



Proteome Sciences plc 

Proteome Sciences Closes Research Contract with Takeda

28th October 2009 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that Takeda Pharmaceutical Company Limited ("Takeda") has signed a contract to use PS Biomarker Services™ for a preclinical study.

Proteome Sciences has a strong track-record in the discovery / validation of biomarkers and rapid assay development in neurodegenerative and cancer fields and will apply its proprietary isobaric Tandem Mass Tags® in combination with its mass spectrometric workflows for the Takeda contract.

Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:

"PS Biomarker Services is ideally placed to undertake biomarker programmes at clinical/preclinical stages and we are pleased to be working with Takeda on this project".

Ends

About Proteome Sciences:

Proteome Sciences is a leading biomarker CRO providing protein biomarker discovery, validation and assay development services. The Company's PS Biomarker Services™  uses its proprietary isobaric Tandem Mass Tags (TMT®) and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed in weeks and are suitable for screening 10's to 100's of candidate biomarkers in validation studies. Assays for validated biomarkers can be rapidly developed using the same isotope dilution mass spectrometry format, or can be transferred for immunoassay development.

The Company's own research is focused on neurological and neurodegenerative conditions and it has discovered and patented blood biomarkers in stroke and brain damage as well as several cancers, solid organ transplant rejection and Alzheimer's disease. Proteome Sciences is based in Cobham, UK with facilities in London and Frankfurt.

For further information please contact: